OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2000 Individual Investigator Grant Recipient – Iman Osman

Iman Osman, M.D.
New York University School of Medicine
Hypoxia Inducible Factor-1 alpha (HIF-1): A Potential New Prognostic Marker for Advanced Ovarian Cancer and Target of Treatment

Project Summary

This project focuses on understanding the biologic basis of advanced ovarian cancer. Specifically, Dr. Osman will study whether the aggressiveness of advanced ovarian cancer and its resistance to current drug therapies are associated with increased activity of a factor known as Hypoxia-inducible factor 1alpha (HIF-1α). Tissues from patients will be tested to determine the levels of HIF-1α within the ovarian cancer compared to adjacent normal tissues. Findings may lead to a new prognostic marker of advanced ovarian cancer and a potential therapeutic target in the treatment of advanced disease.

This grant is awarded in memory of Madeline Kahn and has been made possible by loving contributions in her memory, and with additional generous support from The Kaleidoscope of Hope Foundation.